🎉 M&A multiples are live!
Check it out!

Gilead Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Gilead Sciences and other public comps.

See Gilead Sciences Valuation Multiples

Gilead Sciences Overview

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).


Founded

1987

HQ

United States of America
Employees

18K+

Website

gilead.com

Financials

LTM Revenue $28.3B

LTM EBITDA $9.7B

EV

$138B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Gilead Sciences Financials

Gilead Sciences has a last 12-month revenue of $28.3B and a last 12-month EBITDA of $9.7B.

In the most recent fiscal year, Gilead Sciences achieved revenue of $27.1B and an EBITDA of $10.5B.

Gilead Sciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Gilead Sciences valuation multiples based on analyst estimates

Gilead Sciences P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $27.3B $27.1B $28.3B $28.3B XXX
Gross Profit $20.7B $21.6B $20.6B XXX XXX
Gross Margin 76% 80% 73% XXX XXX
EBITDA $8.9B $10.5B $9.2B $9.7B XXX
EBITDA Margin 32% 39% 32% 34% XXX
Net Profit $6.2B $4.6B $5.7B XXX XXX
Net Margin 23% 17% 20% XXX XXX
Net Debt $21.4B $19.8B $18.9B XXX XXX

Financial data powered by Morningstar, Inc.

Gilead Sciences Stock Performance

As of February 7, 2025, Gilead Sciences's stock price is $96.

Gilead Sciences has current market cap of $120B, and EV of $138B.

See Gilead Sciences trading valuation data

Gilead Sciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$138B $120B XXX XXX XXX XXX $4.75

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Gilead Sciences Valuation Multiples

As of February 7, 2025, Gilead Sciences has market cap of $120B and EV of $138B.

Gilead Sciences's trades at 4.9x LTM EV/Revenue multiple, and 14.3x LTM EBITDA.

Analysts estimate Gilead Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Gilead Sciences and 10K+ public comps

Gilead Sciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $138B XXX XXX XXX
EV/Revenue 4.9x XXX XXX XXX
EV/EBITDA 15.0x XXX XXX XXX
P/E 21.6x XXX XXX XXX
P/E/Growth 0.6x XXX XXX XXX
EV/FCF 13.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gilead Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Gilead Sciences Valuation Multiples

Gilead Sciences's NTM/LTM revenue growth is 1%

Gilead Sciences's revenue per employee for the last fiscal year averaged $1.5M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Gilead Sciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Gilead Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Gilead Sciences and other 10K+ public comps

Gilead Sciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 4% XXX XXX XXX XXX
EBITDA Margin 32% XXX XXX XXX XXX
EBITDA Growth -13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 33% XXX XXX XXX XXX
Revenue per Employee $1.5M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 21% XXX XXX XXX XXX
Opex to Revenue 44% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Gilead Sciences Public Comps

See valuation multiples for Gilead Sciences public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Gilead Sciences M&A and Investment Activity

Gilead Sciences acquired  XXX companies to date.

Last acquisition by Gilead Sciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Gilead Sciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Gilead Sciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Gilead Sciences

When was Gilead Sciences founded? Gilead Sciences was founded in 1987.
Where is Gilead Sciences headquartered? Gilead Sciences is headquartered in United States of America.
How many employees does Gilead Sciences have? As of today, Gilead Sciences has 18K+ employees.
Who is the CEO of Gilead Sciences? Gilead Sciences's CEO is Mr. Daniel P. O'Day.
Is Gilead Sciences publicy listed? Yes, Gilead Sciences is a public company listed on NAS.
What is the stock symbol of Gilead Sciences? Gilead Sciences trades under GILD ticker.
When did Gilead Sciences go public? Gilead Sciences went public in 1992.
Who are competitors of Gilead Sciences? Similar companies to Gilead Sciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Gilead Sciences? Gilead Sciences's current market cap is $120B
What is the current revenue of Gilead Sciences? Gilead Sciences's last 12-month revenue is $28.3B.
What is the current EBITDA of Gilead Sciences? Gilead Sciences's last 12-month EBITDA is $9.7B.
What is the current EV/Revenue multiple of Gilead Sciences? Current revenue multiple of Gilead Sciences is 4.9x.
What is the current EV/EBITDA multiple of Gilead Sciences? Current EBITDA multiple of Gilead Sciences is 14.3x.
What is the current revenue growth of Gilead Sciences? Gilead Sciences revenue growth between 2023 and 2024 was 4%.
Is Gilead Sciences profitable? Yes, Gilead Sciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.